Agilent Technologies (NYSE:A) Price Target Raised to $135.00 at TD Cowen

Agilent Technologies (NYSE:A) had its price target raised by analysts at TD Cowen to $135.00 in a note issued to investors on Thursday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the medical research company’s stock. TD Cowen’s target price indicates a potential upside of 37.17% from the company’s previous close.

Several other research analysts also recently commented on A. Barclays cut their price objective on shares of Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a report on Thursday. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Citigroup increased their target price on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Robert W. Baird lowered their target price on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Finally, Bank of America lowered their target price on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $146.25.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock traded down $8.64 on Thursday, reaching $98.42. 623,187 shares of the company traded hands, compared to its average volume of 1,827,490. Agilent Technologies has a 52 week low of $96.43 and a 52 week high of $155.35. The company has a 50 day moving average of $125.62 and a 200 day moving average of $134.48. The firm has a market capitalization of $28.06 billion, a PE ratio of 22.75, a PEG ratio of 2.79 and a beta of 1.19. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Equities analysts forecast that Agilent Technologies will post 5.57 earnings per share for the current year.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the company’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the sale, the director now owns 35,737 shares in the company, valued at approximately $4,161,931.02. This trade represents a 4.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,638 shares of company stock worth $731,229 over the last 90 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. CKW Financial Group lifted its stake in shares of Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. Global X Japan Co. Ltd. lifted its stake in shares of Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after buying an additional 116 shares in the last quarter. Redwood Park Advisors LLC bought a new position in shares of Agilent Technologies in the fourth quarter worth approximately $27,000. Lee Danner & Bass Inc. bought a new position in shares of Agilent Technologies in the fourth quarter worth approximately $29,000. Finally, Sunbelt Securities Inc. lifted its stake in shares of Agilent Technologies by 640.0% in the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock worth $30,000 after buying an additional 192 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.